10X Genomics Inc

TXG remains in a Stage 2 advancing uptrend with accelerating momentum and rising EMAs, but recent parabolic steepening and extreme overbought conditions advise patience. Price is pulling back into the rising EMA zone on light volume, presenting a better entry opportunity on a shallow correction rather than chasing current highs.

• ↑Q1’26 revenue $151M (+9% YoY); consumables up 13% YoY
• ↑Gross margin rose to 70% from 68% YoY, reflecting pricing power
• ↓Shares trading at ~$39 vs fair value ~$20, implying 94% overvaluation